Midcareer Investigator Award

职业生涯中期研究员奖

• 批准号: 8074017
• 负责人: MATTHEW RAYMOND SMITH
• 金额: $ 19.55万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-05 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8074017
• 关键词: Applications Grants; Award; Cancer Center; Cancer Survivor; Cancer Survivorship; Cardiovascular Diseases; Clinical; Clinical Research; Diabetes Mellitus; Disease; Faculty; Funding; General Hospitals; Genitourinary system; Malignant Neoplasms; Malignant neoplasm of prostate; Massachusetts; Mentors; Metastatic Neoplasm to the Bone; Morbidity - disease rate; Peer Review; Prevention; Public Health; Research; Research Personnel; Time; cancer therapy; novel; oncology; patient oriented research; prevent; programs

DESCRIPTION (provided by applicant): This Midcareer Investigator Award application seeks support to provide Dr. Matthew Smith with protected time to devote to patient-oriented research and to act as an effective research mentor for clinical fellows and junior faculty. The candidate is the Clinical Research Director in Genitourinary Oncology at Massachusetts General Hospital and Co-Director of the Clinical Research in Genitourinary Malignancies for Dana-Farber Harvard Cancer Center (DF/HCC). His clinical research program focuses on cancer survivorship, prevention and treatment of bone metastases, and novel therapies for advanced prostate cancer. He has a strong record of patient-oriented research, independent peer-reviewed funding, and successful mentoring. The timing of this application coincides with the new directions in the candidate's patient-oriented research program, additional successful grant applications, recent selection of a new trainee, and the planned expansion of mentoring activities. The broad long-term objective of this application is to advance both the patient-oriented research program and mentoring activities of the candidate. The Specific Aims are: 1. To decrease disease and treatment-related morbidity in cancer survivors, to treat and prevent bone metastases, and to develop novel therapies for advanced prostate cancer. 2. To evaluate mechanism(s) of treatment-related diabetes and cardiovascular disease in prostate cancer survivors, a new direction in the candidate's patient-oriented research program. 3. To mentor new investigators in patient-oriented research. This research program may advance public health by developing new strategies to treat prostate cancer and to prevent bone metastases, a major cause of prostate cancer morbidity. In addition, this research program may help decrease the burden of cancer treatment for prostate cancer survivors.

描述(由申请人提供)：这份职业生涯中期研究员奖申请寻求支持，为马修·史密斯博士提供保护的时间，致力于以患者为导向的研究，并作为临床研究员和初级教员的有效研究导师。候选人是马萨诸塞州总医院泌尿生殖系统肿瘤学临床研究主任和达纳-法伯哈佛癌症中心泌尿生殖系统恶性肿瘤临床研究联席主任。他的临床研究计划侧重于癌症存活率、骨转移的预防和治疗，以及晚期前列腺癌的新疗法。他在以患者为导向的研究、独立的同行评审资金和成功的指导方面有着良好的记录。这一申请的时机与候选人以患者为导向的研究计划的新方向、额外的成功拨款申请、最近选择的新学员以及计划中的指导活动的扩大不谋而合。 这项申请的广泛长期目标是促进以患者为中心的研究计划和候选人的指导活动。 具体目标是： 1.减少癌症幸存者的疾病和治疗相关发病率，治疗和预防骨转移，并开发晚期前列腺癌的新疗法。 2.评估前列腺癌幸存者治疗相关糖尿病和心血管疾病的机制(S)，这是候选人以患者为导向的研究计划的一个新方向。 3.在以病人为中心的研究中指导新的研究者。 这项研究计划可能会通过开发治疗前列腺癌和预防骨转移的新策略来促进公众健康，骨转移是前列腺癌发病率的主要原因。此外，这项研究计划可能有助于减轻前列腺癌幸存者的癌症治疗负担。